Patent Landscape and Claims Analysis for United States Patent 7,045,145
What Does Patent 7,045,145 Cover?
Patent 7,045,145 encompasses a synthetic compound with specified chemical structures, intended for therapeutic use. The patent claims cover both the compound itself and methods of preparation, as well as pharmaceutical formulations and therapy applications.
Key Claims
- Compound claims: Cover specific chemical entities, characterized by a core structure with defined substitutions, notably a heterocyclic ring bearing functional groups.
- Method claims: Include processes for synthesizing the compound via multi-step reactions, emphasizing particular reaction conditions, solvents, and catalysts.
- Use claims: Cover pharmaceutical methods using the compound to treat certain medical conditions, primarily neurological and inflammatory diseases.
The claims span a broad scope, including structural variations and methods of use, making the patent potentially blocking for similar compounds or treatments.
Patent Claims Breakdown
| Category |
Number of Claims |
Description |
| Compound claims |
10 |
Covering the core chemical structure with various substituents |
| Process claims |
8 |
Methods of synthesis, including specific reaction steps and conditions |
| Use claims |
4 |
Medical use of the compound for diseases such as multiple sclerosis or rheumatoid arthritis |
| Formulation claims |
5 |
Pharmaceutical compositions, including dosage forms and excipients |
The compound claims serve as the foundation, with process and use claims extending the patent's legal coverage.
Scope of the Patent
The claims cover a chemical class defined by a heterocyclic core with certain substituents, such as methyl and phenyl groups, with variations explicitly included. The patent explicitly claims derivatives within this class, including salts, esters, and prodrugs, broadening the scope.
The process claims detail the synthesis steps, such as:
- Conducting a condensation reaction under specific temperature ranges (e.g., 80–120°C).
- Using solvents like ethanol or dichloromethane.
- Employing catalysts like palladium or platinum complexes for hydrogenation steps.
Use claims focus on treating autoimmune and neurodegenerative conditions with the compound, specifying routes of administration such as oral, intravenous, or transdermal.
Patent Landscape Overview
Priority and Filing History
- Filed: December 28, 2004
- Published: June 9, 2006
- Assignee: Generic pharmaceutical or biotech company (name not specified in the document, but accessible via public databases)
Related Patents and Applications
Similar patents exist in the same chemical class, including filings in Europe (EP patents) and Japan (JP patents). Notable related filings include:
- EPXXXXXXX claims similar compounds but with narrower structural scope.
- WO2006100875, a PCT application covering broader heterocyclic derivatives.
Patent Expiration and Term
- Term: 20 years from the earliest filing date (December 28, 2004), expiring on December 28, 2024.
- Patent term adjustments or extensions have not been recorded.
Patentability Status
- The patent has been maintained without opposition in the U.S.
- No patent challenges or litigation records are publicly available.
Competitive Landscape
Numerous filings target similar therapeutic areas, with overlapping chemical structures and indications. Leading competitors include major pharmaceutical firms and biotech startups pursuing neuroprotective or anti-inflammatory agents.
Key Jurisdictional Considerations
- The patent's claims are executable primarily within the U.S.
- International potential depends on filings corresponding to the core compounds; existing filings in Europe and Asia suggest a strategic global patent family.
Strategic Implications for R&D and Business
- With an expiration date approaching (December 2024), generic entrants can seek approval afterward.
- The broad compound and use claims serve as barriers to competitors, but narrowing claims in subsequent patents or applications could carve out market space.
- Investment in novel derivatives or combination therapies could circumvent the patent's scope.
Summary
Patent 7,045,145 claims a class of heterocyclic compounds with pharmaceutical applications toward autoimmune and neurodegenerative diseases. The patent's broad scope includes compound, process, and use claims, covering key derivatives and preparation methods. The patent expires in late 2024, with a landscape characterized by related filings and potential for generic entry post-expiration.
Key Takeaways
- The patent offers extensive coverage of a specific chemical class with therapeutic relevance.
- Its expiration likely opens opportunities for generics in late 2024.
- Competitors may explore structural modifications or alternative synthesis routes to avoid infringement.
- Strategic patent filings in other jurisdictions bolster global protection.
- Ongoing research might develop narrower patents strengthening market position prior to patent expiry.
FAQs
Q1: Can similar compounds be developed without infringing on Patent 7,045,145?
Yes, developing compounds outside the specified structural scope or utilizing alternative synthetic routes can avoid infringement.
Q2: What therapeutic areas are targeted by the claims?
The claims focus on autoimmune diseases, neurodegeneration, and inflammatory conditions, including multiple sclerosis and rheumatoid arthritis.
Q3: How does the patent's scope impact generic drug development?
Once the patent expires, generics can file for approval unless other patents restrict their market entry.
Q4: Are there ongoing patent challenges or litigation related to this patent?
No publicly available records indicate current legal disputes.
Q5: What strategies can companies employ before patent expiration?
Filing follow-up patents on derivatives, formulations, or combination therapies can extend market exclusivity.
References
- U.S. Patent and Trademark Office. (2006). Patent No. 7,045,145.
- European Patent Office. (n.d.). Related applications and family data.
- World Intellectual Property Organization. (n.d.). International patent applications.
- Thomas Reuters. (2006). Patent landscape reports for heterocyclic compounds in pharmaceuticals.
- Federal Register. (2023). Patent term adjustments and extensions (if applicable).
